(Q34180945)

31 July 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure (English)

1 reference

31 July 2017

1 reference

1 reference

Smith BS

1

1 reference

PubMed ID

11248789

31 July 2017

Gandhi PJ

series ordinal

2

1 reference

31 July 2017

1 February 2001

1 reference

Journal of Thrombosis and Thrombolysis

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

1

1 reference

31 July 2017

39-48

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1008904310194

31 July 2017

0 references

cites work

Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis

1 reference

12 December 2020

Low molecular weight heparins: practical considerations

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

1 reference

12 December 2020

Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

12 December 2020

Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension

1 reference

12 December 2020

Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations

1 reference

12 December 2020

Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation

1 reference

12 December 2020

Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure

1 reference

12 December 2020

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Contemporary laboratory monitoring of low molecular weight heparins.

1 reference

12 December 2020

Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

1 reference

12 December 2020

An evaluation of the biological response to Fraxiparine, (a low molecular weight heparin) in the healthy individual

1 reference

12 December 2020

The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers

1 reference

12 December 2020

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

1 reference

12 December 2020

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers

1 reference

12 December 2020

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

12 December 2020

Preclinical differentiation of low molecular weight heparins.

1 reference

12 December 2020

Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase

1 reference

12 December 2020

Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers

1 reference

12 December 2020

Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha

1 reference

12 December 2020

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group

1 reference

12 December 2020

Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

12 December 2020

Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency

1 reference

12 December 2020

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

12 December 2020

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

12 December 2020

Pharmacological activities of heparin chains: should our past knowledge be revised?

1 reference

12 December 2020

Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function

1 reference

12 December 2020

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

12 December 2020

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

12 December 2020

Drug prescribing for patients with changing renal function

1 reference

12 December 2020

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

1 reference

12 December 2020

Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility

1 reference

12 December 2020

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

1 reference

12 December 2020

Effect of computerized physician order entry and a team intervention on prevention of serious medication errors

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects

1 reference

12 December 2020

Disposition of 14C-eptifibatide after intravenous administration to healthy men

1 reference

12 December 2020

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1008904310194

1 reference

PubMed ID

11248789

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11248789